You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 14, 2025

On Target Labs Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for ON TARGET LABS

ON TARGET LABS has one approved drug.

There are six US patents protecting ON TARGET LABS drugs.

There are thirty-five patent family members on ON TARGET LABS drugs in twelve countries.

Summary for On Target Labs
International Patents:35
US Patents:6
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for On Target Labs

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
On Target Labs CYTALUX pafolacianine sodium SOLUTION;INTRAVENOUS 214907-001 Nov 29, 2021 RX Yes Yes 10,881,747 ⤷  Try for Free Y Y ⤷  Try for Free
On Target Labs CYTALUX pafolacianine sodium SOLUTION;INTRAVENOUS 214907-001 Nov 29, 2021 RX Yes Yes 9,254,341 ⤷  Try for Free Y Y ⤷  Try for Free
On Target Labs CYTALUX pafolacianine sodium SOLUTION;INTRAVENOUS 214907-001 Nov 29, 2021 RX Yes Yes 9,333,270 ⤷  Try for Free Y Y ⤷  Try for Free
On Target Labs CYTALUX pafolacianine sodium SOLUTION;INTRAVENOUS 214907-001 Nov 29, 2021 RX Yes Yes 9,341,629 ⤷  Try for Free Y Y ⤷  Try for Free
On Target Labs CYTALUX pafolacianine sodium SOLUTION;INTRAVENOUS 214907-001 Nov 29, 2021 RX Yes Yes ⤷  Try for Free ⤷  Try for Free
On Target Labs CYTALUX pafolacianine sodium SOLUTION;INTRAVENOUS 214907-001 Nov 29, 2021 RX Yes Yes 9,789,208 ⤷  Try for Free Y Y ⤷  Try for Free
On Target Labs CYTALUX pafolacianine sodium SOLUTION;INTRAVENOUS 214907-001 Nov 29, 2021 RX Yes Yes 9,061,057 ⤷  Try for Free Y Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: On Target Labs – Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, staying ahead of the competition is crucial for success. On Target Laboratories, a biotechnology company specializing in intraoperative molecular imaging agents, has emerged as a key player in the field of cancer detection and treatment. This comprehensive analysis delves into On Target Labs' market position, strengths, and strategic insights, providing valuable information for industry professionals and investors alike.

The Rise of On Target Laboratories

On Target Laboratories has carved out a unique niche in the pharmaceutical landscape by focusing on the development of targeted intraoperative molecular imaging agents. These innovative compounds are designed to illuminate cancer cells during surgery, enabling surgeons to more accurately identify and remove cancerous tissue.

A Game-Changing Approach to Cancer Surgery

The company's flagship product, CYTALUX (pafolacianine injection), has gained significant attention in the medical community. As the only FDA-approved molecular imaging agent that illuminates lung and ovarian cancer during surgery, CYTALUX represents a major breakthrough in cancer treatment[8].

"This investment empowers us to accelerate the commercialization of our novel technology, further solidifying our position at the forefront of intraoperative molecular imaging," said Ben Lundgren, President and CEO of On Target Laboratories[10].

Market Position and Competitive Advantage

On Target Laboratories has positioned itself as a leader in the field of intraoperative molecular imaging. The company's focus on developing targeted agents that can illuminate cancer cells during surgery sets it apart from competitors in the pharmaceutical industry.

Unique Value Proposition

By providing surgeons with a tool to visually identify cancer cells in real-time, On Target Laboratories addresses a critical need in cancer treatment. This unique approach offers several advantages:

  1. Improved surgical precision
  2. Potential for more complete tumor removal
  3. Reduced risk of leaving behind cancerous tissue

Strategic Partnerships and Collaborations

On Target Laboratories has forged strategic partnerships with key players in the medical technology sector. For example, the company's collaboration with Stryker, which recently introduced the 1788 Platform – the only minimally invasive surgical camera currently cleared for use with CYTALUX – demonstrates its commitment to advancing the field of cancer surgery[10].

Financial Strength and Investor Confidence

The recent completion of a $30 million Series C financing round underscores the strong investor confidence in On Target Laboratories' technology and market potential[10]. This significant investment will play a crucial role in accelerating the commercialization of CYTALUX and expanding the company's market presence.

Diverse Investor Base

The funding round attracted support from both new and existing investors, including:

  • H.I.G. Capital
  • The Hurvis Group
  • Johnson & Johnson Innovation – JJDC, Inc.
  • Pension Fund of the Christian Church
  • 3B Future Health Fund
  • Elevate Ventures
  • Olympus Innovation Ventures

This diverse investor base reflects the broad appeal of On Target Laboratories' technology and its potential to transform cancer surgery.

Regulatory Milestones and Market Access

On Target Laboratories has achieved significant regulatory milestones that enhance its market position and potential for growth.

FDA Approval

The FDA approval of CYTALUX for use in ovarian and lung cancer surgery represents a major achievement for On Target Laboratories. This regulatory green light opens up substantial market opportunities and validates the company's technology.

New Technology Add-On Payment (NTAP)

In August 2023, the Centers for Medicare & Medicaid Services (CMS) granted a new technology add-on payment (NTAP) for CYTALUX use in ovarian and lung cancer surgery[8]. This designation provides additional reimbursement to hospitals, potentially expanding access to the technology for more patients.

"Under NTAP, CMS will provide hospitals with additional payment of up to 65 percent of the average cost of CYTALUX, which is expected to expand access of the technology to more patients[10]."

Competitive Landscape Analysis

To fully appreciate On Target Laboratories' market position, it's essential to consider the broader competitive landscape in the pharmaceutical and biotechnology sectors.

Key Competitors

While On Target Laboratories has a unique position in the intraoperative molecular imaging space, it faces competition from larger pharmaceutical companies developing cancer treatments and diagnostic tools. Some potential competitors include:

  1. Roche
  2. Novartis
  3. Merck
  4. Bristol Myers Squibb
  5. AstraZeneca

Competitive Advantages

On Target Laboratories' focus on intraoperative imaging sets it apart from many of these larger competitors. The company's advantages include:

  1. Specialized expertise in molecular imaging
  2. FDA-approved product specifically for cancer surgery
  3. Strong intellectual property portfolio
  4. Strategic partnerships with medical technology companies

Market Trends and Future Outlook

The pharmaceutical industry is constantly evolving, and several key trends are likely to impact On Target Laboratories' future growth and market position.

Precision Medicine

The trend towards personalized or precision medicine aligns well with On Target Laboratories' approach. By providing tools that allow for more precise cancer detection and removal, the company is well-positioned to capitalize on this growing market trend.

Advancements in Imaging Technology

Ongoing advancements in imaging technology, including artificial intelligence and machine learning applications, could create new opportunities for On Target Laboratories to enhance its products and expand its market reach.

Increasing Focus on Surgical Outcomes

As healthcare systems worldwide place greater emphasis on improving surgical outcomes and reducing complications, technologies like CYTALUX that enhance surgical precision are likely to see increased adoption.

Research and Development Pipeline

On Target Laboratories' future success will depend in part on its ability to continue innovating and expanding its product portfolio. While specific details of the company's R&D pipeline are not publicly available, it's likely that the company is exploring:

  1. Applications of its technology to other types of cancer
  2. Enhancements to the CYTALUX formulation
  3. Development of new molecular imaging agents
  4. Potential combination therapies or diagnostic tools

Challenges and Potential Risks

Despite its strong market position and innovative technology, On Target Laboratories faces several challenges and potential risks:

Market Adoption

Convincing surgeons and healthcare systems to adopt new technologies can be a slow process. On Target Laboratories will need to invest in education and training to drive adoption of CYTALUX.

Regulatory Hurdles

As the company expands into new indications or markets, it will face additional regulatory challenges and approval processes.

Competition from Larger Pharmaceutical Companies

While On Target Laboratories currently has a unique position in the market, larger pharmaceutical companies with greater resources could potentially enter the space and pose a competitive threat.

Reimbursement Challenges

Despite the NTAP designation, ensuring consistent and adequate reimbursement for CYTALUX across different healthcare systems and payers could present ongoing challenges.

Strategic Recommendations

Based on this analysis, several strategic recommendations emerge for On Target Laboratories:

  1. Expand Indications: Pursue research and clinical trials to expand the use of CYTALUX to other types of cancer surgery.

  2. Strengthen Partnerships: Continue to forge strategic partnerships with medical technology companies to enhance the integration of CYTALUX with surgical imaging systems.

  3. Invest in Education: Develop comprehensive education and training programs for surgeons to drive adoption of CYTALUX.

  4. Explore International Markets: Investigate opportunities for expansion into international markets, particularly in regions with high cancer incidence rates.

  5. Diversify Product Portfolio: Consider developing complementary products or technologies that leverage the company's expertise in molecular imaging.

Key Takeaways

  • On Target Laboratories has established a strong market position with its innovative intraoperative molecular imaging agent, CYTALUX.
  • The company's recent $30 million Series C financing and NTAP designation demonstrate strong investor confidence and regulatory support.
  • Strategic partnerships, particularly in the medical technology sector, enhance On Target Laboratories' competitive advantage.
  • The company faces challenges in market adoption and potential competition from larger pharmaceutical firms.
  • Future success will depend on expanding indications, strengthening partnerships, and continuing to innovate in the field of molecular imaging.

FAQs

  1. What is CYTALUX and how does it work? CYTALUX is an FDA-approved molecular imaging agent that illuminates lung and ovarian cancer cells during surgery, helping surgeons more accurately identify and remove cancerous tissue.

  2. How does On Target Laboratories' technology differ from traditional cancer imaging methods? Unlike traditional imaging methods that are performed before surgery, On Target Laboratories' technology provides real-time visualization of cancer cells during the surgical procedure itself.

  3. What is the significance of the New Technology Add-On Payment (NTAP) for CYTALUX? The NTAP designation provides additional reimbursement to hospitals using CYTALUX, potentially expanding access to the technology for more patients.

  4. How might advancements in artificial intelligence impact On Target Laboratories' technology? AI could potentially enhance the effectiveness of CYTALUX by improving image analysis and helping surgeons more accurately interpret the illuminated cancer cells.

  5. What are the potential applications of On Target Laboratories' technology beyond ovarian and lung cancer? While specific plans are not public, the company could potentially explore applications in other types of cancer surgery, as well as in non-cancer indications where precise tissue identification is crucial.

Sources cited: [8] https://www.prnewswire.com/news-releases/on-target-laboratories-granted-new-technology-add-on-payment-ntap-for-cytalux-pafolacianine-injection-in-ovarian-and-lung-cancer-indications-301897364.html [10] http://buildingindiana.com/stories/on-target-laboratories-secures-30m-for-new-cancer-imaging-agent,2741

Last updated: 2025-02-13

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.